Ameritas Investment Partners’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-3,701
| Closed | -$16.7K | – | 3223 |
|
|
2025
Q2 | $16.7K | Hold |
3,701
| – | – | ﹤0.01% | 2737 |
|
|
2025
Q1 | $16.4K | Hold |
3,701
| – | – | ﹤0.01% | 2638 |
|
|
2024
Q4 | $29K | Hold |
3,701
| – | – | ﹤0.01% | 2474 |
|
|
2024
Q3 | $48.7K | Hold |
3,701
| – | – | ﹤0.01% | 2206 |
|
|
2024
Q2 | $44.7K | Hold |
3,701
| – | – | ﹤0.01% | 2203 |
|
|
2024
Q1 | $60.2K | Buy |
3,701
+1,056
| +40% | +$14.2K | ﹤0.01% | 2043 |
|
|
2023
Q4 | $18K | Hold |
2,645
| – | – | ﹤0.01% | 2623 |
|
|
2023
Q3 | $14.4K | Hold |
2,645
| – | – | ﹤0.01% | 2683 |
|
|
2023
Q2 | $18K | Hold |
2,645
| – | – | ﹤0.01% | 2617 |
|
|
2023
Q1 | $13.3K | Hold |
2,645
| – | – | ﹤0.01% | 2621 |
|
|
2022
Q4 | $11.7K | Hold |
2,645
| – | – | ﹤0.01% | 2769 |
|
|
2022
Q3 | $38K | Hold |
2,645
| – | – | ﹤0.01% | 2182 |
|
|
2022
Q2 | $40K | Hold |
2,645
| – | – | ﹤0.01% | 2141 |
|
|
2022
Q1 | $31K | Hold |
2,645
| – | – | ﹤0.01% | 2353 |
|
|
2021
Q4 | $43K | Hold |
2,645
| – | – | ﹤0.01% | 2228 |
|
|
2021
Q3 | $75K | Hold |
2,645
| – | – | ﹤0.01% | 1871 |
|
|
2021
Q2 | $89K | Hold |
2,645
| – | – | ﹤0.01% | 1795 |
|
|
2021
Q1 | $80K | Hold |
2,645
| – | – | ﹤0.01% | 1786 |
|
|
2020
Q4 | $131K | Hold |
2,645
| – | – | 0.01% | 1411 |
|
|
2020
Q3 | $102K | Hold |
2,645
| – | – | ﹤0.01% | 1413 |
|
|
2020
Q2 | $114K | Buy |
2,645
+616
| +30% | +$23.3K | 0.01% | 1338 |
|
|
2020
Q1 | $53K | Hold |
2,029
| – | – | ﹤0.01% | 1625 |
|
|
2019
Q4 | $63K | Buy |
2,029
+257
| +15% | +$7.6K | ﹤0.01% | 1781 |
|
|
2019
Q3 | $46K | Hold |
1,772
| – | – | ﹤0.01% | 1931 |
|
|
2019
Q2 | $41K | Buy |
1,772
+1,197
| +208% | +$27.5K | ﹤0.01% | 2029 |
|
|
2019
Q1 | $15K | Hold |
575
| – | – | ﹤0.01% | 2537 |
|
|
2018
Q4 | $12K | Buy |
+575
| New | +$13.2K | ﹤0.01% | 2605 |
|
Other funds holding YMAB
Ameritas Investment Partners's YMAB Position: Q3 2025 in Review
Ameritas Investment Partners sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 3,701 shares — an estimated $16.7K sold.
Ameritas Investment Partners first reported a position in YMAB in Q4 2018 and held it in 27 quarters. The position peaked at $131K in Q4 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Ameritas Investment Partners reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Ameritas Investment Partners sold 3,701 Y-mAbs Therapeutics shares in Q3 2025, an estimated $16.7K.
- Ameritas Investment Partners first reported a position in Y-mAbs Therapeutics in Q4 2018 and held it in 27 quarters.
- Ameritas Investment Partners's Y-mAbs Therapeutics position peaked at $131K in Q4 2020.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Ameritas Investment Partners's 13F filing for Q3 2025, filed 10 Nov 2025.